Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Sumitovant_Biopharma
|
| gptkbp:CEO |
gptkb:James_Robinson
|
| gptkbp:focusesOn |
oncology
urology |
| gptkbp:foundedIn |
2017
|
| gptkbp:headquartersLocation |
Irvine, California, United States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Urovant Sciences
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:parentCompany |
gptkb:Sumitovant_Biopharma
|
| gptkbp:product |
gptkb:vibegron
gemtesa |
| gptkbp:publiclyTraded |
false
|
| gptkbp:specializesIn |
overactive bladder treatments
urinary health |
| gptkbp:website |
https://www.urovant.com/
|
| gptkbp:bfsParent |
gptkb:Roivant_Sciences
|
| gptkbp:bfsLayer |
5
|